Both are tenofovir prodrugs with similar efficacy. TAF (alafenamide) achieves higher intracellular drug concentration at lower plasma levels, with favourable bone and renal safety. TDF (disoproxil) has decades of follow-up data and is significantly cheaper. The choice depends on bone density, renal function, and cost considerations.
Have a follow-up question?
Reply via the quote wizard with case-specific questions and a coordinator will answer in 1–2 business days.